Henry Han

What is current guideline-recommended medical therapy for #HFrEF? #ESCCongress @escardio

Safety and Feasibility of the eLymTM System for Interstitial #Decongestion in Acute Decompensated #HeartFailure: Primary results of the #DELTA-HF trial #EJHF @ESC_Journals academic.oup.com/eurjhf/advance… @HanCardiomd @AmrAbdin10 @GiuseppeGalati_

@GianluSava @HFA_President @escardio Congratulations @GianluSava 🎊 🎉 #HFA @ESCardioNews @escardio

It has been a great #HeartFailure2026 congress. So honored to have been elected @HFA_President for 2028-2030. I’m excited for the opportunity and hopeful that I can live up to the expectations of our wonderful community. Thank you for your trust. @escardio @HanCardiomd

#GPRASP1 Safeguards Endothelial Aspartate Metabolism to Prevent #PulmonaryHypertension Associated With Heart Failure With Preserved Ejection Fraction #HFpEF @CircAHA ahajournals.org/doi/10.1161/CI…

#ARNI in #HFpEF and Secondary Mitral Regurgitation: the PRAISE-MR Randomized Trial 📍Sa/Val ⬆️ exercise hemodynamics in HFpEF + AFMR, ⤵️ mPAP/CO slope vs SOC (−0.93 mmHg/L/min; 95% CI −1.80 to −0.07; p=0.035). 📍At 6 months, Sa/Val improved peak VO₂ (+0.9 vs −0.6; p=0.002) and KCCQ (+10 vs +2), with ⬇️ #NTproBNP, LA volume (p<0.001), and less exercise MR (p=0.020). ahajournals.org/doi/10.1161/CI… @CircAHA

🫀#MR in #HF is far more than “mild, moderate, severe”. ⚠️Accurate MR assessment directly influences HF management & outcomes. Excellent overview by @anatimoteo46040 at #HeartFailure26 on how we should assess secondary MR in HF: 📍Mechanism matters: Ventricular vs atrial MR, differentiate early 📍MR grading must be multiparametric, Never rely on a single number alone. 📍Secondary MR is dynamic, Severity may change after: GDMT optimization, CRT, rhythm/rate control, decongestion. ⚠️Reassess before intervention decisions. 📍Multimodality imaging matters, each provide complementary information on anatomy, mechanism, ventricular remodeling, procedural suitability 📍Heart Team discussion is essential. 📍Quantitative parameters matter most when deciding advanced therapies @escardio @EACVIPresident @VictoriaDe32503 #EchoFirst #whyCMR #YesCCT #3DEcho #HeartFailure

🫀DIGIT-HF subgroup analysis presented at #HeartFailure26 by Prof. Udo Bavendiek, explored the efficacy & safety of #digitoxin in #HFrEF according to #AFib status: 📍HFrEF➕AF represented a clinically higher-risk phenotype with more comorbidities & symptoms 📍Digitoxin ⬇️ the composite of all-cause death or first HF hospitalization irrespective of AF status 📍In AF subgroups: ARR 10.5%, NNT 10 for the primary endpoints 📍The apparent benefit seemed more pronounced in patients with AF, mainly driven by reductions in all-cause mortality @escardio @HFA_President @MarcoMetra @JBauersachsMD

#PVR for the diagnosis of pulmonary vascular disease in heart failure 📍PVR >2 Wood Units is strongly associated with worse outcomes in HF and identifies #CpcPH 📍PAP decay curve analysis and changes in CO can refine interpretation of PVR in HF patients. @ESC_Journals academic.oup.com/eurheartj/adva…

1,855 stable #LVAD patients from #MOMENTUM-3, RAAS inhibitor therapy at 1 month 📍The benefit of #RAASi in #LVAD patients was driven mainly by less non-surgical bleeding (aRR 0.82, 95% CI 0.73–0.90). 📍Patients with sustained RAASi exposure had even greater risk reduction (aRR 0.67, 95% CI 0.56–0.80; p<0.0001) academic.oup.com/eurheartj/adva… #EHJ @ESC_Journals @EJHFEiC #HeartFailure26

Blinded withdrawal of randomized treatment with low-dose #digoxin or placebo in patients with #HeartFailure: the #DECISION trial 📍After stopping digoxin, event rates jumped from 5.7 to 42.8 events/100 patient-years, while placebo remained stable (6.5 to 5.9). #Digoxin withdrawal also increased HR, lowered SBP, and raised #NTproBNP academic.oup.com/eurheartj/adva… @ehj_ed @ESC_Journals #HeartFailure26

🫀 What happens when long-term low-dose #digoxin is suddenly withdrawn? Blinded withdrawal analysis from the #DECISION trial presented at #HeartFailure26 by Prof. Peter van der Meer: 📍Digoxin withdrawal was associated with a ~7x increase in worsening HF events over just 6 weeks 📍14 worsening HF events occurred after digoxin withdrawal vs only 2 events in placebo withdrawal 📍Withdrawal was accompanied by: ⬆️HR,⬇️ SBP, ⬆️NT-proBNP, ⬇️eGFR 📍⚠️caution when stopping long-term low-dose digoxin in pts with HF & LVEF <=50% @escardio @HFA_President @jozinetm

Association of patient-centred remote monitoring with clinical outcomes in patients with prior hospitalization: the TELESAT PRIOR-HF study academic.oup.com/eurjhf/advance… #EJHF @EJHFEiC

Honored to co-author this commentary in @ESC_Journals expanding on the emerging cardio–pancreatic axis in heart failure. Seeing our work spark academic dialogue is truly special. Thanks @HanCardiomd for the opportunity. doi.org/10.1093/eschf/…

Guideline-recommended medical therapy efficacy according to use of digoxin: RALES, EMPHASIS-HF, PARADIGM-HF, and DAPA-HF trials 👇 ow.ly/s71V50YWYQb @FaiezZANNAD @HFA_President #HeartFailure26 #HFA_ESC

💦Decongestion is one of the key targets in the treatment of decompensated HF. The results of post-hoc analysis of multicentre RCT “Duel-HF” that compared decongestion by EF and the effects of tora vs furo per os💊 presented today at #HeartFailure2026 @escardio @YMareev

🫀Durable #MCS improves survival in advanced HF, but managing complications remains central to long-term success. Clinical pearls from @kevin_damman at #HeartFailure26: 📍Patients with durable MCS live longer with better QoL & pts reported outcomes 📍Risks remain substantial: bleeding, stroke, infection, device dysfunction & RV failure 📍HM3 markedly reduced pump thrombosis & device-related complications vs older devices 📍RV failure remains one of the most important long-term complications 📍Protocolized RV protection strategies may reduce events 📍Overall mortality risk is still lower with durable MCS vs advanced HF without MCS 📍Additional long-term challenges include ventricular arrhythmias, aortic regurgitation & complexity of non-cardiac surgery #LVAD @escardio @jozinetm @MarcoMetra @HFA_President @WilfriedMullens

Update on heart transplantation: a clinical consensus statement of the Advanced Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology #EJHF @ESC_Journals academic.oup.com/eurjhf/advance… @HanCardiomd @AmrAbdin10 @GiuseppeGalati_

#HFC members are at ESC HF 2026 in Barcelona 🇪🇸 Kicking off tomorrow with key discussions in heart failure. Check out our members’ agenda for May 9 👇 #ESCHeartFailure2026 #HFA2026

Anticoagulants beyond coagulation This must-read Invited Review explores both intended & potential unintended effects of anticoagulants, including influence on #vascular pathology & #cardiac function through pleiotropic mechanisms academic.oup.com/cardiovascres/… #CardiovascularResearch